"10.1371_journal.pone.0051645","plos one","2012-12-13T00:00:00Z","Kurt-Wolfram Sühs; Katharina Hein; Jens R Pehlke; Barbara Käsmann-Kellner; Ricarda Diem","Department of Neurology, Saarland University, Homburg, Germany; Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany; Department of Neurology, Georg-August University, Göttingen, Germany; Department of Addiction Disorders, LWL Clinic Münster, Münster, Germany; Department of Ophthalmology, Saarland University, Homburg, Germany; Department of Neuro-oncology, University Clinic Heidelberg, Heidelberg, Germany","Conceived and designed the experiments: KWS RD. Performed the experiments: KWS JRP BKK RD. Analyzed the data: KWS KH JRP BKK RD. Contributed reagents/materials/analysis tools: KH. Wrote the paper: RD.","RD has received travel expenses from Biogen Idec, and consultancy fees from Synthon BV, KWS and KH have received travel expenses from Biogen Idec, Bayer Healthcare, and TEVA. JRP and BKK have nothing to declare. This study was supported by research grants from Bayer Healthcare, Leverkusen, Germany, and Merck Serono GmbH, Darmstadt. Betaferon is marketed by Bayer, and Rebif is marketed by Merck Serono. There are no further patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Kurt-Wolfram Sühs","KWS",5,TRUE,2,4,5,1,TRUE,TRUE,FALSE,0,NA,FALSE
